Strategic Blueprint LLC Acquires Shares of 2,738 Edwards Lifesciences Co. (NYSE:EW)

Strategic Blueprint LLC bought a new position in shares of Edwards Lifesciences Co. (NYSE:EW) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 2,738 shares of the medical research company’s stock, valued at approximately $203,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in EW. Algert Global LLC lifted its position in shares of Edwards Lifesciences by 38.4% during the second quarter. Algert Global LLC now owns 4,616 shares of the medical research company’s stock valued at $426,000 after purchasing an additional 1,280 shares in the last quarter. Centaurus Financial Inc. lifted its position in shares of Edwards Lifesciences by 13.2% during the 2nd quarter. Centaurus Financial Inc. now owns 1,822 shares of the medical research company’s stock worth $168,000 after buying an additional 212 shares in the last quarter. Czech National Bank boosted its stake in shares of Edwards Lifesciences by 6.9% in the 3rd quarter. Czech National Bank now owns 122,715 shares of the medical research company’s stock worth $8,098,000 after buying an additional 7,883 shares during the last quarter. Harbor Investment Advisory LLC increased its position in shares of Edwards Lifesciences by 16.7% during the third quarter. Harbor Investment Advisory LLC now owns 16,383 shares of the medical research company’s stock valued at $1,081,000 after acquiring an additional 2,339 shares during the last quarter. Finally, GAMMA Investing LLC lifted its holdings in Edwards Lifesciences by 21.6% during the third quarter. GAMMA Investing LLC now owns 4,105 shares of the medical research company’s stock worth $271,000 after acquiring an additional 730 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on EW shares. Truist Financial restated a “hold” rating and issued a $78.00 price objective (up previously from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Daiwa America downgraded shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 30th. Stifel Nicolaus upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and boosted their target price for the company from $75.00 to $90.00 in a research note on Thursday. Morgan Stanley restated an “equal weight” rating and set a $70.00 price target on shares of Edwards Lifesciences in a research note on Friday, October 11th. Finally, Piper Sandler dropped their price objective on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, Edwards Lifesciences has a consensus rating of “Hold” and an average price target of $79.19.

Edwards Lifesciences Trading Down 1.1 %

Shares of EW stock opened at $72.41 on Monday. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The business’s fifty day moving average is $72.49 and its 200 day moving average is $69.85. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The company has a market capitalization of $42.71 billion, a PE ratio of 10.45, a price-to-earnings-growth ratio of 3.65 and a beta of 1.11.

Insider Buying and Selling at Edwards Lifesciences

In other news, insider Larry L. Wood sold 25,000 shares of Edwards Lifesciences stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the sale, the insider now directly owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. The trade was a 11.18 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Daniel J. Lippis sold 500 shares of the stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,594,475.64. This represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 33,000 shares of company stock valued at $2,195,180 in the last 90 days. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.